Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Stock Quote Today & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

By working with Health Canada and the FDA to approve the optimization of the clinical study design, analysis and reporting structure of Study II early in the process, Theralase® is able to much better align the clinical data collected in Study II with best practices and current expectations of the Canadian and US regulators; thereby, helping to avoid difficult to address questions at final review time

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer

Current News (TSXV:TLT)

Theralase(R) Closes Non-Brokered Private Placement

Accesswire 5 days ago

Theralase(R) Extends Warrants

Accesswire 8 days ago

Three Canadian small-caps stocks for a contrarian investment

Trevor Abes  October 11, 2024

Latest data from bladder cancer study to propel future growth

Jocelyn Aspa October 10, 2024

Theralase’s bladder cancer drug under investigation in clinical study

Jonathon Brown October 7, 2024

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Accesswire October 7, 2024
View More News ››

To date, the Theralase® Study II clinical data has demonstrated best-in-class performance for a single agent, providing high efficacy, durable response and a high safety profile, with no serious adverse events directly related to RuvidarTM or the TLC-3200 Medical Laser System

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer

Opinion & Analysis (TSXV:TLT)

Pharmaceutical company treats bladder cancer with new tech

Ryan Dhillon January 8, 2024

Theralase is raising up to $5.3M to complete bladder cancer study

Coreena Robertson November 6, 2023

For Better or Worse? On the Verge of a New Era in Investing

Stockhouse Editorial April 1, 2021

Buzz on the Bullboards: A Big Picture Look at Small-Cap Opportunities

Stockhouse Editorial February 18, 2021

Buzz on the Bullboards: Tracking the Big Movers of 2020

Stockhouse Editorial December 17, 2020

Buzz on the Bullboards: T’is the Season for a Rebound?

Stockhouse Editorial December 3, 2020
View More Opinion ››

Bullboard Posts (TSXV:TLT)

RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook

It's totally surreal.  To think that we're sitting next to a soon to be preeminent FDA endosed molecule, potentially...
BlueFranky - 7 hours ago

RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook

Correction... 7)  Achieving efficacy & durability, but at the expense of one or a combination        of...
CancerSlayer - 8 hours ago

RE:RE:RE:RE:RE:RE:RE:2025 Outlook

Certainly....if we were to put a lens on just clinical development stage/progress, being a company with a nearly completed Ph II (&...
CancerSlayer - 8 hours ago

RE:RE:RE:RE:RE:RE:RE:RE:2025 Outlook

The outlook for 2025 is not good it is not better it is the BEST.  My gut feeling, we will get BTD in 2024.  We may even AA...
Infinity - 10 hours ago

RE:RE:RE:RE:RE:RE:RE:2025 Outlook

11000 volume. .285 c after 15 years of  company existence boy that is a good  stuff.Keep pumping boys
Alamir1111 - 10 hours ago

RE:RE:RE:RE:Went back 17 pages on Dumbles post pages

Guys. Please. DDW has always been a "devil's advocate" type poster. He is who he is and we can read the posts or not. I...
DJDawg - 10 hours ago
View more Bullboard ››

Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250